Deposition of pressurized suspension aerosols inhaled through extension devices. 1981

S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke

Only a small fraction of the dose from a pressurized aerosol inhaler reaches the lung, because most is deposited on the upper airways by inertial impaction. We have investigated the effects on aerosol deposition of two spacer devices (a 10-cm tube and a 22-cm cone) by incorporating teflon particles (mass median aerodynamic diameter, 3.2 micrometer) labeled with 99mTc into pressurized canisters. Ten subjects with obstructive airway disease inhaled the aerosol in a controlled manner from a conventional actuator alone or in combination with the tube or the cone. Radioaerosol distribution was measured using a shadowshield whole body counter. Deposition on the conducting airways was significantly improved by both spacers, but alveolar deposition was unchanged. Initial oropharyngeal deposition was reduced by both spacers in all 10 patients. We conclude that the spacer devices may have a role to play in aerosol therapy by increasing drug availability to the lung, while at the same time decreasing unwanted drug deposition in the oropharynx.

UI MeSH Term Description Entries
D008173 Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent. Obstructive Lung Diseases,Obstructive Pulmonary Diseases,Lung Disease, Obstructive,Obstructive Lung Disease,Obstructive Pulmonary Disease,Pulmonary Disease, Obstructive,Pulmonary Diseases, Obstructive
D012138 Respiratory Therapy Care of patients with deficiencies and abnormalities associated with the cardiopulmonary system. It includes the therapeutic use of medical gases and their administrative apparatus, environmental control systems, humidification, aerosols, ventilatory support, bronchopulmonary drainage and exercise, respiratory rehabilitation, assistance with cardiopulmonary resuscitation, and maintenance of natural, artificial, and mechanical airways. Inhalation Therapy,Therapy, Inhalation,Therapy, Respiratory,Inhalation Therapies,Respiratory Therapies,Therapies, Inhalation,Therapies, Respiratory
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000305 Adrenal Cortex Hormones HORMONES produced by the ADRENAL CORTEX, including both steroid and peptide hormones. The major hormones produced are HYDROCORTISONE and ALDOSTERONE. Adrenal Cortex Hormone,Corticoid,Corticoids,Corticosteroid,Corticosteroids,Cortex Hormone, Adrenal,Hormone, Adrenal Cortex,Hormones, Adrenal Cortex
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D013667 Technetium The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m Technetium 99m,99m, Technetium
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions

Related Publications

S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke
January 1973, Archives of internal medicine,
S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke
January 1982, European journal of respiratory diseases. Supplement,
S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke
December 1981, Chest,
S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke
February 1982, Clinical physics and physiological measurement : an official journal of the Hospital Physicists' Association, Deutsche Gesellschaft fur Medizinische Physik and the European Federation of Organisations for Medical Physics,
S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke
January 2004, Paediatric respiratory reviews,
S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke
January 1985, The Annals of occupational hygiene,
S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke
December 1976, The Journal of pharmacy and pharmacology,
S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke
January 1970, Inhaled particles,
S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke
January 1980, Bulletin europeen de physiopathologie respiratoire,
S P Newman, and F Morén, and D Pavia, and F Little, and S W Clarke
September 1975, Inhaled particles,
Copied contents to your clipboard!